Date: 2011-10-27
Type of information: Establishment of a new subsidiary in the EU
Compound: pre-clinical oncology in vivo solutions for researchers
Company: Oncodesign (France) Taconic (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
promotion
Action mechanism:
Disease:
Details: Taconic, a provider of life sciences solutions, and Oncodesign, an innovative leader in the discovery of novel anti-cancer therapies, have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services. The combined Taconic-Oncodesign portfolio gives oncology researchers access to powerful tools to advance their drug discovery and improve efficacy testing. This unique offering features a broad spectrum of in vivo models - including Oncodesign's Chi Mice® - state-of-the-art preclinical models grafted with patient-derived xenografts and a human immune system, to reproduce the human environment - as well as Taconic's genetically modified models of oncology and the DuPont™ OncoMouse®, providing access to sophisticated spontaneous tumor models.
To complement this broad range of oncology-specific models, Taconic and Oncodesign will provide highly sophisticated imaging technologies - from optical bioluminescent imaging to MRI, PET and SPECT Pharm'Image® technologies for monitoring tumor growth in vivo and ex vivo, and biomarker discovery - along with in vivo and in vitro pharmacology research services. In addition, both partners will combine their expertise in the use of immunodeficient mouse models and co-develop novel applications of Taconic\'s CIEA NOG mouse®. These super-immunodeficient mice will be reconstituted with a human immune system and patient-derived tumor tissues, providing an additional tool for testing of novel cancer therapeutics in a physiological relevant setting.
Financial terms:
Latest news:
